GlobeNewswire by notified

Crown Bioscience and Data Sciences International (DSI) Partner to Advance Metabolic Disease Research Using an Implanted Telemetry Device for Long-Term Blood Glucose Monitoring

Share

SANTA CLARA, Calif., Nov. 23, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation cardiovascular and metabolic disease research, announces the successful development of an enhanced method for preclinical obesity and type 2 diabetes studies in partnership with Data Sciences International (DSI). Crown Bioscience's clinically relevant models and DSI's HD-XG implantable glucose device combine to create a superior approach to preclinical metabolic disease research.

Recently published work in the Journal of Endocrinological Investigation and Nature's Scientific Reports demonstrates the advantages of a new method using DSI's HD-XG implantable glucose device and Crown Bioscience's models of spontaneous and diet-induced diabetes. The HD-XG device allows for continuous, long-term measurement of blood glucose, temperature, and locomotor activity and eliminates stress inducing blood sampling that can inadvertently skew glucose levels and cause blood volume to decline. The published data support use of this superior method to thoroughly imonitor glucose levels in Crown Bioscience's clinically relevant models of human metabolic disease.

"We are excited to provide researchers with this powerful new method to advance preclinical obesity and diabetes programs," said Jim Wang, M.D., Crown Bioscience's Senior Vice President Cardiovascular and Metabolic Diseases (CVMD) Research. "By leveraging Crown Bioscience's models to recapitulate human metabolic disease and DSI's HD-XG device to reliably investigate changes in blood glucose, researchers can gain unpresented insight into the pathophysiology of metabolic diseases and the pharmacology of related investigational compounds."

"We are pleased to collaborate with CrownBio to further promote the adoption of continuous glucose telemetry in research studies," said Eric Rieux, Vice President Global Sales and Marketing at DSI. "We share a common goal of helping scientists better understand blood glucose levels, and ultimately develop better drugs, devices, and therapies for humans."

For more information on CrownBio's commitment to furthering the field of cardiovascular and metabolic drug discovery, visit https://www.crownbio.com/cvmd

About Crown Bioscience Inc.

Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.

About DSI

DSI provides a complete preclinical platform to assess physiological data for research ranging from basic, to drug discovery, and drug development. DSI is the leading provider of telemetry systems, pulmonary solutions, associated software platforms, and services.

Media Enquiries:

Jody Barbeau

Crown Bioscience Inc. marketing@crownbio.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Crown Bioscience Inc. via Globenewswire

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Brookfield Corporation Completes Annual Filings19.3.2024 01:55:08 CET | Press release

BROOKFIELD, NEWS, March 18, 2024 (GLOBE NEWSWIRE) -- Brookfield Corporation (“Brookfield”) (NYSE: BN, TSX: BN) today announced that it has filed its 2023 annual materials on Form 40-F, including its audited financial statements and management’s discussion and analysis for the year ended December 31, 2023, with the SEC on EDGAR as well as with the Canadian securities authorities on SEDAR. These documents are also available at www.brookfield.com and a hardcopy will be provided to shareholders free of charge upon request. About Brookfield Corporation Brookfield Corporation is a leading global investment firm focused on building long-term wealth for institutions and individuals around the world. We have one of the largest pools of discretionary capital globally, which is deployed across our three core businesses – asset management, insurance solutions, and our operating businesses. Through our core businesses, we invest in real assets that form the backbone of the global economy to deliver

Schneider Electric Collaborates with NVIDIA on Designs for AI Data Centers18.3.2024 23:12:33 CET | Press release

• New reference designs will offer a robust framework for implementing NVIDIA’s accelerated computing platform within data centers;• Designs will optimize performance, scalability, and energy efficiency; Schneider Electric, the leader in the digital transformation of energy management and automation, today announced a collaboration with NVIDIA to optimize data center infrastructure and pave the way for groundbreaking advancements in edge artificial intelligence (AI) and digital twin technologies. Schneider Electric will leverage its expertise in data center infrastructure and NVIDIA’s advanced AI technologies to introduce the first publicly available AI data center reference designs. These designs are set to redefine the benchmarks for AI deployment and operation within data center ecosystems, marking a significant milestone in the industry's evolution. With AI applications gaining traction across industries, while also demanding more resources than traditional computing, the need for

Hexagon Purus ASA: Issue of shares under the Company's LTIP plan18.3.2024 21:35:00 CET | Press release

The long term incentive plan of December 2020 (the "2020 LTIP") for Hexagon Purus ASA (the "Company") vested upon approval of the 2023 annual financial statements. Consequently, the Company's board of directors, has resolved to issue in total 909,742 new shares to the entitled employees pursuant to the authorization to issue shares granted on 25 May 2023. Following registration of the share issue, the Company's registered share capital will be NOK 27,770,719.80, divided into 277,709,198 shares, each having a face value of NOK 0.10. 541,242 of the new shares were issues to PDMRs, as further specified in the attached forms. For additional information, please contact: Salman Alam, Chief Financial Officer, Hexagon Purus Telephone: +47 476 12 713 | salman.alam@hexagonpurus.com Mathias Meidell, Investor Relations Director, Hexagon Purus Telephone: +47 909 82 242 | mathias.meidell@hexagonpurus.com About Hexagon Purus: Hexagon Purus enables zero emission mobility for a cleaner energy future. T

Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D18.3.2024 21:00:00 CET | Press release

LEGEND achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with empagliflozin arm compared to placebo.Statistical significance was also achieved on several markers of liver injury, markers of glucose and lipid metabolism, as well as hepatic steatosis.Patients treated with lanifibranor in combination with empagliflozin maintained a stable weight throughout the 24 weeks study, addressing the moderate, metabolically healthy, weight gain that has been observed in some patients treated with lanifibranor.Treatment with lanifibranor alone and in combination with empagliflozin decreased the ratio of visceral abdominal fat to subcutaneous fat, reflecting a shift from pro-inflammatory visceral fat towards metabolically healthy adipose tissue.The treatment with lanifibranor 800mg/once daily alone or in combination with empagliflozin for 24 weeks was well tolerated, with no safety concerns reported.Inventiva will host an

Driving Excellence: C.K. McWhorter Grants Bentley Motors McWhorter Family Trust Warrant of Automotive Distinction18.3.2024 20:56:28 CET | Press release

LONDON, March 18, 2024 (GLOBE NEWSWIRE) -- The McWhorter Family Trust proudly announces its partnership with Bentley Motors, heralding a new era of automotive excellence. In a momentous decision, the Trust bestows upon Bentley Motors the emblem of automotive distinction, recognizing its unwavering commitment to luxury, innovation, and craftsmanship. Incorporating Bentley Motors into the McWhorter Family Trust’s Portfolio: The addition of Bentley Motors to the McWhorter Family Trust’s prestigious portfolio signifies a strategic expansion into the realm of automotive luxury. This pivotal decision underscores the Trust's dedication to investing in brands that epitomize excellence and timeless sophistication. Furthermore, it opens doors to potential indirect investment opportunities in Bentley Motors through avenues such as automotive technology and events. Strategic Investment Approach of C.K. McWhorter: C.K. McWhorter, in orchestrating the structure of a Single Family Office (SFO), strat

HiddenA line styled icon from Orion Icon Library.Eye